Ingredient or product comparison
Research Compound Comparison Summary
Primary pathway MC4R→cAMP/CREB→BDNF→TrkB-PI3K-Akt Ctr1→Nrf2→ARE→HO-1/NQO1/GCL; Keap1 oxidation Onset of neuroprotection Delayed: 12–24h for full BDNF-TrkB effect Biphasic: immediate chelation (0–30 min) + Nrf2 (4–8h) Primary injury target Trophic deficit; apop
This source-based comparison does not add ratings or recommend a winner.
- Primary pathway
- MC4R→cAMP/CREB→BDNF→TrkB-PI3K-Akt
- Ctr1→Nrf2→ARE→HO-1/NQO1/GCL; Keap1 oxidation
- Onset of neuroprotection
- Delayed: 12–24h for full BDNF-TrkB effect
- Biphasic: immediate chelation (0–30 min) + Nrf2 (4–8h)
- Primary injury target
- Trophic deficit; apoptosis; axonal die-back
- Oxidative stress; lipid peroxidation; Fenton radicals
- Secondary effects
- Neuroplasticity; cognition; CREB-driven gene expression
- Anti-inflammation via NF-κB; ECM remodelling; collagen
- MCAO/R infarct reduction
- −38–44%
- −42–48%
- Combined MCAO/R infarct reduction
- −62–68% (additive, independent pathways confirmed)
- Key blocker
- K252a (TrkB); SHU9119 (MC4R)
- ML385 (Nrf2); tetrathiomolybdate (Cu²⁺ chelation)
- Best acute injury use
- Post-ischaemic trophic support; TBI secondary neuroprotection
- Acute oxidative burst suppression; oedema; BBB
- Best chronic disease use
- Neurodegeneration (BDNF deficit); cognitive decline; cholinergic loss
- Oxidative neurodegeneration; α-syn oligomer biology; lipid peroxidation
- Combination rationale
- Orthogonal mechanisms → additive protection; sequential timing optimal (GHK-Cu acute, Semax 6–24h onward)
- 🔗 Related Reading: For Semax’s full BDNF and cognitive biology profile, see our Semax UK Research Guide.